# Ticagrelor Versus Cilostazol in Large-vessel Ischemic Stroke

Study · id `cardio:ct-nct06202755` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06202755](<https://clinicaltrials.gov/study/NCT06202755>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06202755

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 580 participants.

## Technical summary

Registry record NCT06202755. Randomized; double masking; primary purpose treatment. Start 2024-03-30 (actual); primary completion 2025-06-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 580 participants (planned count; ClinicalTrials.gov record NCT06202755, source copy `cardio:ctgov-nct06202755-2024-08-20`, retrieved 2026-10-26)
- Started: 2024-03-30 (actual) (ClinicalTrials.gov record NCT06202755, source copy `cardio:ctgov-nct06202755-2024-08-20`, retrieved 2026-10-26)
- Primary completion: 2025-06-12 (anticipated) (ClinicalTrials.gov record NCT06202755, source copy `cardio:ctgov-nct06202755-2024-08-20`, retrieved 2026-10-26)
- Completion: 2025-07-12 (anticipated) (ClinicalTrials.gov record NCT06202755, source copy `cardio:ctgov-nct06202755-2024-08-20`, retrieved 2026-10-26)
- Countries: Egypt (ClinicalTrials.gov record NCT06202755, source copy `cardio:ctgov-nct06202755-2024-08-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06202755-2024-08-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: Ticagrelor Versus Cilostazol in Large-vessel Ischemic Stroke
- Condition: Ischemic Stroke
- Intervention (Drug): Ticagrelor 90 MG
- Intervention (Drug): Cilostazol 100 MG
- Lead sponsor: Kafrelsheikh University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Kafrelsheikh University (`cardio:org-kafrelsheikh-university`)

## Provenance

Content hash: d28ac78e7a721d5b9b97f35056d71e982d5f3d7ba66e5f6f973aabed8961e802
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
